Celcuity announced that the phase 3 VIKTORIA-1 trial met its primary endpoint in the PIK3CA-mutant cohort, showing a statistically significant and clinically meaningful improvement in progression-free survival with gedatolisib plus fulvestrant and palbociclib compared with alpelisib plus fulvestrant.
The full dataset remains awaited and will be presented as a late-breaking oral abstract at ASCO 2026, making this a topline result rather than a fully interpretable efficacy dataset.
Read About PIC3CA Testing on OncoDaily
Why This Matters After CDK4/6 Progression
Progression after aromatase inhibitor plus CDK4/6 inhibitor remains a major challenge in HR-positive, HER2-negative metastatic breast cancer. Many patients with PIK3CA-mutant disease receive PI3K-pathway therapy, but current approved approaches generally target a single component of the PI3K/AKT/mTOR pathway.
Gedatolisib takes a broader approach. It is an investigational multi-target PAM pathway inhibitor designed to inhibit all four class I PI3K isoforms as well as mTORC1 and mTORC2.
VIKTORIA-1 Study Design
VIKTORIA-1 is a phase 3, open-label, randomized trial evaluating gedatolisib-based regimens in patients with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior CDK4/6 inhibitor plus aromatase inhibitor therapy. This represents a clinically important post-CDK4/6 setting, where resistance to endocrine therapy has already emerged and treatment options are limited.
The study focuses on both biomarker-defined and broader populations, with separate analyses for the PIK3CA-mutant cohort, a key subgroup given the role of the PI3K pathway in endocrine resistance.
In this cohort, patients were randomized in a 3:3:1 ratio to receive:
- Gedatolisib + fulvestrant + palbociclib (triplet)
- Gedatolisib + fulvestrant (doublet)
- Alpelisib + fulvestrant (control)
The triplet arm explores whether combining endocrine therapy, CDK4/6 inhibition, and full PI3K/AKT/mTOR blockade can overcome resistance more effectively. The doublet arm evaluates whether comprehensive pathway inhibition alone is sufficient without CDK4/6 re-challenge.
Using alpelisib plus fulvestrant as the comparator allows direct assessment against current PI3K-targeted standard of care. The primary endpoint is progression-free survival, with additional analyses expected to clarify the role of treatment intensity and pathway inhibition in this setting.
What Was Announced
According to Celcuity, the gedatolisib triplet met the primary efficacy endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared with alpelisib plus fulvestrant.
The gedatolisib doublet also showed a statistically significant and clinically meaningful improvement in progression-free survival compared with alpelisib plus fulvestrant, although this comparison was not part of the primary hierarchical efficacy analysis.
Both gedatolisib regimens were reported to be generally well tolerated, with manageable safety profiles and no new safety signals.
What We Still Need to See
The press release does not provide median progression-free survival, hazard ratios, response rates, duration of response, discontinuation rates, or detailed adverse event data. These details are essential to understand the true clinical magnitude of benefit and how the triplet and doublet compare in practice.
The upcoming ASCO 2026 presentation will be important for answering several key questions: how large the progression-free survival benefit is, whether palbociclib meaningfully adds to gedatolisib plus fulvestrant, how toxicity compares with alpelisib-based therapy, and which patient subgroups derive the greatest benefit.
Why the ASCO 2026 Presentation Will Matter
The VIKTORIA-1 presentation at ASCO 2026 will determine whether this positive topline signal becomes practice-shaping. The most important missing pieces are the exact efficacy estimates and the full safety profile for both gedatolisib regimens.
The triplet result is especially interesting because it includes palbociclib after prior CDK4/6 inhibitor exposure, raising a clinically important question: can CDK4/6 inhibition still add value when paired with more complete PI3K/AKT/mTOR pathway blockade?
The doublet result is also important. If gedatolisib plus fulvestrant shows meaningful benefit with a simpler safety profile, it could become highly relevant for patients who need pathway targeting but may not tolerate a triplet approach.
A Careful Bottom Line
VIKTORIA-1 introduces a potentially important post-CDK4/6 strategy in PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer. For now, the announcement supports cautious optimism rather than immediate practice change.
The full ASCO 2026 data will clarify whether gedatolisib can meaningfully challenge current PI3K-pathway standards and whether comprehensive PAM pathway inhibition represents a new direction in endocrine-resistant metastatic breast cancer.